The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic
(1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted
interval corrected (QT) for heart rate (HR)
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Collaborator:
Covance
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Zamicastat